The versatilityof the LGP nanogel platform also allows for thedelivery of a broad range of therapeutic agentsincluding chemotherapeuticDOX, the apoptosis-inducing ligand TRAIL, and immune checkpoint inhibitorssuch as anti-PD-1 antibodiesmaking it a clinically translatableplatform to enhance treatment efficacy in HCC. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.